Published in Proc Natl Acad Sci U S A on June 05, 2006
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature (2010) 3.39
Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol (2008) 3.18
Src activates Abl to augment Robo1 expression in order to promote tumor cell migration. Oncotarget (2010) 1.52
Energetic dissection of Gleevec's selectivity toward human tyrosine kinases. Nat Struct Mol Biol (2014) 1.24
Sustained suppression of Bcr-Abl-driven lymphoid leukemia by microRNA mimics. Proc Natl Acad Sci U S A (2007) 1.10
Targeting invadopodia to block breast cancer metastasis. Oncotarget (2011) 1.10
Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. J Cell Mol Med (2008) 1.10
In vitro selection of a DNA-templated small-molecule library reveals a class of macrocyclic kinase inhibitors. J Am Chem Soc (2010) 1.06
Computational modeling of allosteric communication reveals organizing principles of mutation-induced signaling in ABL and EGFR kinases. PLoS Comput Biol (2011) 1.06
Molecular dynamics simulations show that conformational selection governs the binding preferences of imatinib for several tyrosine kinases. J Biol Chem (2010) 1.01
The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int J Clin Oncol (2007) 0.98
Vav3 collaborates with p190-BCR-ABL in lymphoid progenitor leukemogenesis, proliferation, and survival. Blood (2012) 0.92
SRC points the way to biomarkers and chemotherapeutic targets. Genes Cancer (2012) 0.88
BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors. Acta Haematol (2009) 0.87
Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. Drug Des Devel Ther (2009) 0.85
Towards a Molecular Understanding of the Link between Imatinib Resistance and Kinase Conformational Dynamics. PLoS Comput Biol (2015) 0.83
Cell treatment and lysis in 96-well filter-bottom plates for screening Bcr-Abl activity and inhibition in whole-cell extracts. J Biomol Screen (2010) 0.79
Overcoming AC220 resistance of FLT3-ITD by SAR302503. Blood Cancer J (2013) 0.79
Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model. Vaccine (2010) 0.78
The cancer treatment revolution. Trans Am Clin Climatol Assoc (2007) 0.77
Evaluating the predictivity of virtual screening for ABL kinase inhibitors to hinder drug resistance. Chem Biol Drug Des (2013) 0.77
A method for screening and validation of resistant mutations against kinase inhibitors. J Vis Exp (2014) 0.76
Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance. Sci Rep (2015) 0.75
Abl kinase constructs expressed in bacteria: facilitation of structural and functional studies including segmental labeling by expressed protein ligation. Mol Biosyst (2012) 0.75
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 20.30
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 13.03
A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol (2005) 12.22
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med (2001) 11.88
Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 11.83
Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science (2000) 9.29
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell (2005) 7.99
Crystal structure of the Src family tyrosine kinase Hck. Nature (1997) 7.66
Three-dimensional structure of the tyrosine kinase c-Src. Nature (1997) 7.62
The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood (2004) 6.92
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell (2003) 5.71
Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell (2003) 5.44
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A (2005) 4.70
Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature (1997) 4.26
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res (2002) 4.19
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood (2002) 4.00
A myristoyl/phosphotyrosine switch regulates c-Abl. Cell (2003) 3.48
Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem Biol (2004) 3.30
Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci U S A (2005) 2.85
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. Cancer Cell (2003) 2.70
Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood (2003) 2.61
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood (2004) 2.61
Autoinhibition of c-Abl. Cell (2002) 1.93
Variation on an Src-like theme. Cell (2003) 1.90
Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood (2005) 1.73
Crosstalk between the catalytic and regulatory domains allows bidirectional regulation of Src. Nat Struct Biol (2000) 1.36
Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res (2002) 1.34
Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors. Cancer Res (2003) 1.04
The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res (2000) 1.00
Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain. Oncogene (2001) 1.00
A screen to identify drug resistant variants to target-directed anti-cancer agents. Biol Proced Online (2003) 0.99
Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds. Chem Biol Drug Des (2006) 0.98
A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: implications for clinical resistance in targeted cancer treatment. Cell Cycle (2005) 0.92
Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate. Arch Pathol Lab Med (2004) 0.87
Monitoring of minimal residual disease in chronic myeloid leukemia. Hematol Oncol Clin North Am (2004) 0.82
Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib. Leuk Res (2004) 0.78
Molecular surveillance of chronic myeloid leukemia patients in the imatinib era - evaluation of response and resistance. Acta Haematol (2004) 0.77
Reprogramming of human somatic cells to pluripotency with defined factors. Nature (2007) 30.84
Disease-specific induced pluripotent stem cells. Cell (2008) 16.95
Selective blockade of microRNA processing by Lin28. Science (2008) 14.39
Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell (2010) 14.18
Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol (2009) 11.18
Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet (2009) 10.54
Somatic coding mutations in human induced pluripotent stem cells. Nature (2011) 9.50
Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell (2009) 8.97
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell (2005) 7.99
Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming. Nat Biotechnol (2009) 7.59
Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature (2007) 7.55
Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature (2011) 7.43
Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell (2011) 7.41
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell (2009) 6.97
Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells. Nat Biotechnol (2009) 6.76
Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35
Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature (2010) 6.06
HoxB4 confers definitive lymphoid-myeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors. Cell (2002) 5.71
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell (2003) 5.71
Lipid-protein interactions in double-layered two-dimensional AQP0 crystals. Nature (2005) 5.44
Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell (2003) 5.44
Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Nat Genet (2010) 5.37
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest (2007) 5.17
The promise of induced pluripotent stem cells in research and therapy. Nature (2012) 5.05
Generation of induced pluripotent stem cells from human blood. Blood (2009) 4.92
Generation of human-induced pluripotent stem cells. Nat Protoc (2008) 4.85
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell (2009) 4.69
The Lin28/let-7 axis regulates glucose metabolism. Cell (2011) 4.65
Derivation of embryonic germ cells and male gametes from embryonic stem cells. Nature (2003) 4.56
Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy. Cell (2002) 4.56
Molecular model for a complete clathrin lattice from electron cryomicroscopy. Nature (2004) 4.48
Determinants of microRNA processing inhibition by the developmentally regulated RNA-binding protein Lin28. J Biol Chem (2008) 4.40
Structural basis for cooperativity in recruitment of MAML coactivators to Notch transcription complexes. Cell (2006) 4.28
Chromatin-modifying enzymes as modulators of reprogramming. Nature (2012) 4.22
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res (2002) 4.19
Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature (2009) 4.14
Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol (2011) 3.97
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A (2011) 3.97
Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature (2009) 3.93
Structure and function of an essential component of the outer membrane protein assembly machine. Science (2007) 3.85
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature (2010) 3.39
Lin28: A microRNA regulator with a macro role. Cell (2010) 3.39
Generation of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology (2010) 3.36
Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells. Nat Biotechnol (2011) 3.25
Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol (2008) 3.18
Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell (2010) 3.08
Lin28 enhances tissue repair by reprogramming cellular metabolism. Cell (2013) 3.08
Broader implications of defining standards for the pluripotency of iPSCs. Cell Stem Cell (2009) 3.03
Biomechanical forces promote embryonic haematopoiesis. Nature (2009) 2.99
Metabolic regulation of protein N-alpha-acetylation by Bcl-xL promotes cell survival. Cell (2011) 2.98
Influence of threonine metabolism on S-adenosylmethionine and histone methylation. Science (2012) 2.98
Aquaporin-0 membrane junctions reveal the structure of a closed water pore. Nature (2004) 2.94
Reprogramming of T cells from human peripheral blood. Cell Stem Cell (2010) 2.93
A role for Lin28 in primordial germ-cell development and germ-cell malignancy. Nature (2009) 2.88
Transplantation of adult mouse iPS cell-derived photoreceptor precursors restores retinal structure and function in degenerative mice. PLoS One (2011) 2.86
Stage-specific signaling through TGFβ family members and WNT regulates patterning and pancreatic specification of human pluripotent stem cells. Development (2011) 2.82
Mechanism of activation and inhibition of the HER4/ErbB4 kinase. Structure (2008) 2.79
A robust approach to identifying tissue-specific gene expression regulatory variants using personalized human induced pluripotent stem cells. PLoS Genet (2009) 2.78
High-efficiency RNA interference in human embryonic stem cells. Stem Cells (2005) 2.76
Lin28a transgenic mice manifest size and puberty phenotypes identified in human genetic association studies. Nat Genet (2010) 2.72
Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes (2005) 2.67
Midbody accumulation through evasion of autophagy contributes to cellular reprogramming and tumorigenicity. Nat Cell Biol (2011) 2.65
Case records of the Massachusetts General Hospital. Case 28-2014. A 39-year-old man with a rash, headache, fever, nausea, and photophobia. N Engl J Med (2014) 2.62
New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell (2008) 2.61
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood (2004) 2.61
Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells (2009) 2.59
Induced pluripotent stem cells--opportunities for disease modelling and drug discovery. Nat Rev Drug Discov (2011) 2.58
Teratoma formation assays with human embryonic stem cells: a rationale for one type of human-animal chimera. Cell Stem Cell (2007) 2.56
Lineage regulators direct BMP and Wnt pathways to cell-specific programs during differentiation and regeneration. Cell (2011) 2.53
Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med (2010) 2.50
Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc Natl Acad Sci U S A (2003) 2.44
Collaboration gets the most out of software. Elife (2013) 2.42
LIF/STAT3 signaling fails to maintain self-renewal of human embryonic stem cells. Stem Cells (2004) 2.37
Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients. Nature (2010) 2.36
Impaired intrinsic immunity to HSV-1 in human iPSC-derived TLR3-deficient CNS cells. Nature (2012) 2.32
Embryonic stem cell-derived hematopoietic stem cells. Proc Natl Acad Sci U S A (2005) 2.28
Molecular basis for interaction of let-7 microRNAs with Lin28. Cell (2011) 2.28
Lin28: primal regulator of growth and metabolism in stem cells. Cell Stem Cell (2013) 2.27
Structure of human O-GlcNAc transferase and its complex with a peptide substrate. Nature (2011) 2.24
Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc Natl Acad Sci U S A (2013) 2.22
Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst (2008) 2.21
Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des (2010) 2.19